Treerita Essali Johnson-Greene net worth and biography

Treerita Johnson-Greene Biography and Net Worth

CFO of Ocugen

Mrs. Johnson-Greene has more than 20 years of healthcare experience. She most recently served as Chief Operating Officer at the Alliance for Regenerative Medicine (ARM) where she led ARM’s operations, finance, and global expansion initiatives to advance the development of engineered cell therapies and genetic medicines and promote access for all patients. Prior to her role at ARM, she was the Vice President of Sales and Qualified Treatment Centers (QTC) at Genetix Biotherapeutics (formerly known as bluebird bio), where she built and scaled pre-commercial U.S. sales and QTC operations teams to support the launch of the ZYNTEGLO™ and SKYSONA™ gene therapy brands. Mrs. Johnson-Greene also held senior leadership positions at Spark Therapeutics and supported the launch of LUXTERNA®. Previously, she held roles in finance, commercial operations, and sales in both North and South America for AstraZeneca. Mrs. Johnson-Greene began her career in strategic consulting with Accenture’s strategy practice.

Mrs. Johnson-Greene earned her MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania, and her undergraduate degree in Electrical Computer Engineering from Drexel University. She serves on the Drexel University Biomed Dean’s Executive Advisory Council and is a guest lecturer for biomedical graduate students.

What is Treerita Essali Johnson-Greene's net worth?: The estimated net worth of Treerita Essali Johnson-Greene is at least $646.04 thousand as of June 15th, 2026. Johnson-Greene owns 521,000 shares of Ocugen stock worth more than $646,040 as of June 19th. This net worth estimate does not reflect any other investments that Johnson-Greene may own. Learn More about Treerita Essali Johnson-Greene's net worth.
How do I contact Treerita Essali Johnson-Greene?: The corporate mailing address for Johnson-Greene and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Treerita Essali Johnson-Greene's contact information.
Has Treerita Essali Johnson-Greene been buying or selling shares of Ocugen?: Within the last three months, Treerita Essali Johnson-Greene has bought $25,830.00 in shares of Ocugen stock. Most recently, on Monday, June 15th, Treerita Essali Johnson-Greene bought 21,000 shares of Ocugen stock. The stock was acquired at an average cost of $1.23 per share, with a total value of $25,830.00. Following the completion of the transaction, the chief financial officer now directly owns 521,000 shares of the company's stock, valued at $640,830. Learn More on Treerita Essali Johnson-Greene's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Treerita Johnson-Greene (CFO), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.
Are insiders buying or selling shares of Ocugen?: In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 21,000 shares worth more than $25,830.00. The most recent insider tranaction occured on June, 15th when CFO Treerita Essali Johnson-Greene bought 21,000 shares worth more than $25,830.00. Insiders at Ocugen own 4.0% of the company. Learn More about insider trades at Ocugen.
Information on this page was last updated on 6/15/2026.

Treerita Essali Johnson-Greene Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/15/2026	Buy	21,000	$1.23	$25,830.00	521,000

Treerita Essali Johnson-Greene Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $1.24

$1.24

$1.32

50 Day Range

MA: $1.49

$1.18

$1.99

2 Week Range

Now: $1.24

$0.90

$2.73

Volume

26,257,190 shs

Average Volume

5,114,256 shs

Market Capitalization

$419.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19